Named for the Roman goddess of wisdom and medicine, Minerva was introduced at the Icahn School of Medicine in 2012. Since then, Minerva has been updated numerous times and researchers have been quick to make use of its capabilities.
Built to Accelerate Discoveries for Researchers
Minerva is now an essential part of over 2,000 workflows and accelerates progress to expand our field of biomedical knowledge. This has translated into new understanding and new therapies for a wide spectrum of disease categories including autism, cancer progression, insulin resistance in diabetics, cardiac care, and psychiatry, to name but a few. Minerva is utilized for over $100 million in funding from the National Institute of Health.
Benchmarked, Optimized, and Finely-Tuned to the Needs of Researchers
Through continual refinement and optimization, we continue to create a computational and data ecosystem that is responsive, reliable, and efficient. We gather valuable input through our regular Minerva Town Halls, our Scientific Advisory Board, 1:1 meetings and training sessions. Through the process of benchmarking the system and engaging in dialogue with our users, Minerva is finely-tuned to the needs of research workflows.
Selected Science Enabled by High Performance Computing
Filizola Lab: Computer-modeled molecular dynamics for opioid receptors
The overall goal of the Filizola Lab's research is to gain insights into the structure, dynamics, and function of certain receptor proteins which are important drug targets. Under the direction of Marta Filizola, PhD, Dean of the Graduate School of Biomedical Sciences at the Icahn School of Medicine at Mount Sinai, the Filizola Lab has harnessed the power of Minerva to create increasingly more complex molecular models and simulations. The Scientific Computing group has also assisted the Filizola Lab in developing state-of-the-art computational methodologies in modeling these processes. Researchers have devoted special attention to opioid receptors, which are important drug targets for pain management, drug abuse/addiction, and mood disorders.
Seaver Center for Autism: Discovering factors for autism in embryonic development
The Seaver Autism Center for Research and Treatment conducts research studies aimed at understanding the multiple causes of autism spectrum disorder (ASD). Scientific Computing helps researchers conduct large scale sequencing and data analysis on a level that would not have been possible only a few years ago. In a recent study, researchers demonstrated that postzygotic mutations (e.g., sporadic genetic lesions that occur very early during embryonic development) are important factors contributing to ASD risk. This study was cited as one of the most important advances in autism in 2017 by a federal advisory committee, the Interagency Autism Coordinating Committee.